Brainstorm Cell Therapeutics agrees to settle shareholder derivative litigation over alleged misleading statements
BCLI•
BCLI•Brainstorm Cell Therapeutics agreed to settle shareholder derivative litigation through corporate governance reforms lasting at least four years. Defendants’ insurers will pay $725,000 in plaintiffs’ attorneys’ fees and expenses, subject to court approval.
The settlement, which requires court approval, calls for corporate governance reforms lasting at least four years. Defendants’ insurers will pay $725,000 in plaintiffs’ attorneys’ fees and expenses, also subject to court approval.
Plaintiffs allege fiduciary breaches involving misleading disclosures about NurOwn’s FDA setbacks, manufacturing deficiencies and safety risks; defendants deny wrongdoing. A federal court hearing on the proposed settlement is scheduled for January 5, 2027, at 10:00 a.m. in New York.